Cartesian Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 9, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CARTESIAN THERAPEUTICS, INC. | ||
| Date: March 9, 2026 | By: | /s/ Carsten Brunn, Ph.D. |
|---|---|---|
| Carsten Brunn, Ph.D. | ||
| President, Chief Executive Officer and Chairman of the Board | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Carsten Brunn, Ph.D. | President, Chief Executive Officer and Chairman of the Board | March 9, 2026 |
| Carsten Brunn, Ph.D. | (Principal Executive Officer) | |
| /s/ Blaine Davis | Chief Financial Officer | March 9, 2026 |
| Blaine Davis | (Principal Financial and Accounting Officer) | |
| /s/ Patrick Zenner | Lead Independent Director | March 9, 2026 |
| Patrick Zenner | ||
| /s/ Timothy C. Barabe | Director | March 9, 2026 |
| Timothy C. Barabe | ||
| /s/ Adrian Bot | Director | March 9, 2026 |
| Adrian Bot | ||
| /s/ Nishan de Silva, M.D. | Director | March 9, 2026 |
| Nishan de Silva, M.D. | ||
| /s/ Murat Kalayoglu, M.D., Ph.D. | Director | March 9, 2026 |
| Murat Kalayoglu, M.D., Ph.D. | ||
| /s/ Kemal Malik MBBS | Director | March 9, 2026 |
| Kemal Malik, MBBS | ||
| /s/ Michael Singer, M.D., Ph.D. | Director | March 9, 2026 |
| Michael Singer, M.D., Ph.D. | ||
| /s/ Timothy Springer, Ph.D. | Director | March 9, 2026 |
| Timothy Springer, Ph.D. | ||
| Index to Consolidated Financial Statements | Pages |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | F-2 |
| Consolidated Balance Sheets at December 31, 2025 and 2024 | F-5 |
| Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2025 and 2024 | F-5 |
| Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders' Deficit for the years ended December 31, 2025 and 2024 | F-6 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2025 and 2024 | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.